Atrium Therapeutics, Inc. (RNA)

Atrium Therapeutics Statistics

Total Valuation

RNA has a market cap or net worth of $198.13 million. The enterprise value is $205.21 million.

Market Cap	198.13M
Enterprise Value	205.21M

Important Dates

The next estimated earnings date is Tuesday, June 9, 2026, after market close.

Earnings Date	Jun 9, 2026
Ex-Dividend Date	n/a

Share Statistics

RNA has 15.51 million shares outstanding.

Current Share Class	15.51M
Shares Outstanding	15.51M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	3.09%
Owned by Institutions (%)	26.14%
Float	15.04M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	10.82
Forward PS	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	11.02
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.07

Current Ratio	0.07
Quick Ratio	0.00
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-399.25%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	148.38%
Weighted Average Cost of Capital (WACC)	9.20%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	2.40
Inventory Turnover	n/a

Taxes

Income Tax	-142,000
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	0.93
52-Week Price Change	n/a
50-Day Moving Average	n/a
200-Day Moving Average	n/a
Relative Strength Index (RSI)	42.55
Average Volume (20 Days)	460,014

Short Selling Information

The latest short interest is 3.02 million, so 6.62% of the outstanding shares have been sold short.

Short Interest	3.02M
Short Previous Month	1.91M
Short % of Shares Out	6.62%
Short % of Float	n/a
Short Ratio (days to cover)	5.03

Income Statement

In the last 12 months, RNA had revenue of $18.62 million and -$49.50 million in losses. Loss per share was -$3.19.

Revenue	18.62M
Gross Profit	-25.65M
Operating Income	-49.63M
Pretax Income	-49.64M
Net Income	-49.50M
EBITDA	-49.31M
EBIT	-49.63M
Loss Per Share	-$3.19

Balance Sheet

Cash & Cash Equivalents	n/a
Total Debt	3.67M
Net Cash	-3.67M
Net Cash Per Share	-$0.24
Equity (Book Value)	-62.71M
Book Value Per Share	-4.04
Working Capital	-38.96M

Cash Flow

In the last 12 months, operating cash flow was -$41.13 million and capital expenditures -$1.45 million, giving a free cash flow of -$42.57 million.

Operating Cash Flow	-41.13M
Capital Expenditures	-1.45M
Depreciation & Amortization	323,000
Net Borrowing	n/a
Free Cash Flow	-42.57M
FCF Per Share	-$2.74

Margins

Gross margin is -137.76%, with operating and profit margins of -266.58% and -265.88%.

Gross Margin	-137.76%
Operating Margin	-266.58%
Pretax Margin	-266.64%
Profit Margin	-265.88%
EBITDA Margin	-264.84%
EBIT Margin	-266.58%
FCF Margin	n/a

Dividends & Yields

RNA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-24.56%
FCF Yield	-21.12%

Analyst Forecast

The average price target for RNA is $66.12, which is 417.78% higher than the current price. The consensus rating is "Buy".

Price Target	$66.12
Price Target Difference	417.78%
Analyst Consensus	Buy
Analyst Count	18
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1